Verteporfin Therapy of Subfoveal Occult Choroidal Neovascularization in AMD Using Delayed Light Application: One-year Results of the VALIO Study

Philip J Rosenfeld, David S. Boyer, Neil M. Bressler, Gary Fish, W. Sanderson Grizzard, Yong Hao, Peter Hnik, Henry L. Hudson, Lawrence Singerman, Jason S. Slakter

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Purpose: To compare photodynamic therapy (PDT) with verteporfin (Visudyne; Novartis Pharma AG, Basel, Switzerland) using either standard or delayed light application. Design: Phase II, multicenter, masked, randomized clinical trial. Methods: Sixty patients with occult with no classic choroidal neovascularization (CNV) resulting from age-related macular degeneration were assigned randomly (1:1) to verteporfin infusion followed by light application either at 15 minutes (standard light) or 30 minutes (delayed light) after the start of the infusion. The assigned treatment was repeated every three months if fluorescein leakage was detected. Results: At month 12, patients lost a mean of 15.7 letters and 11.4 letters from baseline in the standard and delayed light groups, respectively (P = .38). Twelve (52%) of 23 patients in the standard light group and 11 (42%) of 26 in the delayed light group lost at least 15 letters of visual acuity (P = .57). Conclusions: There were no statistically significant differences between verteporfin therapy using the delayed light regimen of 30 minutes or the standard light regimen of 15 minutes in eyes with occult with no classic CNV.

Original languageEnglish
JournalAmerican Journal of Ophthalmology
Volume144
Issue number6
DOIs
StatePublished - Dec 1 2007

Fingerprint

Choroidal Neovascularization
Light
Therapeutics
verteporfin
Photochemotherapy
Macular Degeneration
Fluorescein
Switzerland
Visual Acuity
Randomized Controlled Trials

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Verteporfin Therapy of Subfoveal Occult Choroidal Neovascularization in AMD Using Delayed Light Application : One-year Results of the VALIO Study. / Rosenfeld, Philip J; Boyer, David S.; Bressler, Neil M.; Fish, Gary; Grizzard, W. Sanderson; Hao, Yong; Hnik, Peter; Hudson, Henry L.; Singerman, Lawrence; Slakter, Jason S.

In: American Journal of Ophthalmology, Vol. 144, No. 6, 01.12.2007.

Research output: Contribution to journalArticle

Rosenfeld, Philip J ; Boyer, David S. ; Bressler, Neil M. ; Fish, Gary ; Grizzard, W. Sanderson ; Hao, Yong ; Hnik, Peter ; Hudson, Henry L. ; Singerman, Lawrence ; Slakter, Jason S. / Verteporfin Therapy of Subfoveal Occult Choroidal Neovascularization in AMD Using Delayed Light Application : One-year Results of the VALIO Study. In: American Journal of Ophthalmology. 2007 ; Vol. 144, No. 6.
@article{c73e9f08e3ff4f19993c8d881de4df34,
title = "Verteporfin Therapy of Subfoveal Occult Choroidal Neovascularization in AMD Using Delayed Light Application: One-year Results of the VALIO Study",
abstract = "Purpose: To compare photodynamic therapy (PDT) with verteporfin (Visudyne; Novartis Pharma AG, Basel, Switzerland) using either standard or delayed light application. Design: Phase II, multicenter, masked, randomized clinical trial. Methods: Sixty patients with occult with no classic choroidal neovascularization (CNV) resulting from age-related macular degeneration were assigned randomly (1:1) to verteporfin infusion followed by light application either at 15 minutes (standard light) or 30 minutes (delayed light) after the start of the infusion. The assigned treatment was repeated every three months if fluorescein leakage was detected. Results: At month 12, patients lost a mean of 15.7 letters and 11.4 letters from baseline in the standard and delayed light groups, respectively (P = .38). Twelve (52{\%}) of 23 patients in the standard light group and 11 (42{\%}) of 26 in the delayed light group lost at least 15 letters of visual acuity (P = .57). Conclusions: There were no statistically significant differences between verteporfin therapy using the delayed light regimen of 30 minutes or the standard light regimen of 15 minutes in eyes with occult with no classic CNV.",
author = "Rosenfeld, {Philip J} and Boyer, {David S.} and Bressler, {Neil M.} and Gary Fish and Grizzard, {W. Sanderson} and Yong Hao and Peter Hnik and Hudson, {Henry L.} and Lawrence Singerman and Slakter, {Jason S.}",
year = "2007",
month = "12",
day = "1",
doi = "10.1016/j.ajo.2007.08.017",
language = "English",
volume = "144",
journal = "American Journal of Ophthalmology",
issn = "0002-9394",
publisher = "Elsevier USA",
number = "6",

}

TY - JOUR

T1 - Verteporfin Therapy of Subfoveal Occult Choroidal Neovascularization in AMD Using Delayed Light Application

T2 - One-year Results of the VALIO Study

AU - Rosenfeld, Philip J

AU - Boyer, David S.

AU - Bressler, Neil M.

AU - Fish, Gary

AU - Grizzard, W. Sanderson

AU - Hao, Yong

AU - Hnik, Peter

AU - Hudson, Henry L.

AU - Singerman, Lawrence

AU - Slakter, Jason S.

PY - 2007/12/1

Y1 - 2007/12/1

N2 - Purpose: To compare photodynamic therapy (PDT) with verteporfin (Visudyne; Novartis Pharma AG, Basel, Switzerland) using either standard or delayed light application. Design: Phase II, multicenter, masked, randomized clinical trial. Methods: Sixty patients with occult with no classic choroidal neovascularization (CNV) resulting from age-related macular degeneration were assigned randomly (1:1) to verteporfin infusion followed by light application either at 15 minutes (standard light) or 30 minutes (delayed light) after the start of the infusion. The assigned treatment was repeated every three months if fluorescein leakage was detected. Results: At month 12, patients lost a mean of 15.7 letters and 11.4 letters from baseline in the standard and delayed light groups, respectively (P = .38). Twelve (52%) of 23 patients in the standard light group and 11 (42%) of 26 in the delayed light group lost at least 15 letters of visual acuity (P = .57). Conclusions: There were no statistically significant differences between verteporfin therapy using the delayed light regimen of 30 minutes or the standard light regimen of 15 minutes in eyes with occult with no classic CNV.

AB - Purpose: To compare photodynamic therapy (PDT) with verteporfin (Visudyne; Novartis Pharma AG, Basel, Switzerland) using either standard or delayed light application. Design: Phase II, multicenter, masked, randomized clinical trial. Methods: Sixty patients with occult with no classic choroidal neovascularization (CNV) resulting from age-related macular degeneration were assigned randomly (1:1) to verteporfin infusion followed by light application either at 15 minutes (standard light) or 30 minutes (delayed light) after the start of the infusion. The assigned treatment was repeated every three months if fluorescein leakage was detected. Results: At month 12, patients lost a mean of 15.7 letters and 11.4 letters from baseline in the standard and delayed light groups, respectively (P = .38). Twelve (52%) of 23 patients in the standard light group and 11 (42%) of 26 in the delayed light group lost at least 15 letters of visual acuity (P = .57). Conclusions: There were no statistically significant differences between verteporfin therapy using the delayed light regimen of 30 minutes or the standard light regimen of 15 minutes in eyes with occult with no classic CNV.

UR - http://www.scopus.com/inward/record.url?scp=36249019912&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36249019912&partnerID=8YFLogxK

U2 - 10.1016/j.ajo.2007.08.017

DO - 10.1016/j.ajo.2007.08.017

M3 - Article

C2 - 18036873

AN - SCOPUS:36249019912

VL - 144

JO - American Journal of Ophthalmology

JF - American Journal of Ophthalmology

SN - 0002-9394

IS - 6

ER -